Fasnall

Overview

Fasnall is a selective fatty acid synthase (FASN) inhibitor with an IC 50 of 3.71 μM. Fasnall induces apoptosis in HER2 + breast cancer cell lines. Fasnall shows potent anti-tumor activities.

Application

Products | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Obesity | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Digestive System Disease | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Fatty Acid Synthase (FASN) | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-121250
• CAS No.: 929978-58-5
• Molecular Formula: C19H22N4S
• Molecular Weight: 338.47
• Purity: 99.94%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (7.39 mM); Clear solution
• Availability: In-stock

Source

Original product source